Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Icenticaftor - Novartis

Drug Profile

Icenticaftor - Novartis

Alternative Names: NVP-QBW-251; QBW-251

Latest Information Update: 13 Oct 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis
  • Class Amides; Amines; Antifibrotics; Ethers; Fluorinated hydrocarbons; Pyridines
  • Mechanism of Action Cystic fibrosis transmembrane conductance regulator stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Bronchiectasis; Cystic fibrosis
  • Discontinued Chronic obstructive pulmonary disease

Most Recent Events

  • 13 Oct 2023 700318808- Trial termination info added to KDM and HE
  • 21 Jul 2023 Novartis terminates a phase-II trial in Bronchiectasis in Germany, Spain, China, United Kingdom (PO), due to strategic business decision (NCT04396366)
  • 05 Apr 2023 Discontinued - Phase-II for Chronic obstructive pulmonary disease (In the elderly, In adults) in Poland (PO) before March 2023
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top